Vivian Chua

459 citations
17 papers · 326 indexed · h-index 10
    • Ocular Oncology and Treatments 13
    • Immunotherapy and Immune Responses 2
    • Cancer-related Molecular Pathways 5
    • Drug Transport and Resistance Mechanisms 2
    • Hippo pathway signaling and YAP/TAZ 4
    • Microtubule and mitosis dynamics 3
    • Ubiquitin and proteasome pathways 6
    • Retinal Development and Disorders 2

Vivian Chua

17 papers receiving 323 citations

Peers

Vivian Chua
Comparison fields: 5 of 49
  • Ophthalmology 180
  • Immunology 82
  • Oncology 99
  • Cell Biology 55
  • Molecular Biology 206
Replace Wieke Zuidervaart with:
Wieke Zuidervaart Netherlands
Nikita Dave United States
Berglind O. Einarsdottir Sweden
Helen Snyder United States
Johanne Lade‐Keller Denmark
Richard Yu United States
Julia Vaübel Germany
Aurélie Thuleau France
Mehdi Ghram Canada
Monica Boitano Italy
Vivian Chua relative to Wieke Zuidervaart Netherlands Wieke Zuidervaart's profile →
Citations per field
00.5×12.3×
Wieke Zuidervaart · 1×
Citations per year

Countries citing papers authored by Vivian Chua

Since Specialization
Citations

This map shows the geographic impact of Vivian Chua's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vivian Chua with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vivian Chua more than expected).

Fields of papers citing papers by Vivian Chua

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vivian Chua. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vivian Chua. The network helps show where Vivian Chua may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Vivian Chua, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Vivian Chua Line = papers co-authored together Vivian Chua links everyone, so they are left out of the graph.

All Works

17 of 17 papers shown
#Work
1 20242
2 20244
3 20235
4 20231
5 20232
6 202215
7 202113
8 202018
9 202032
10 202016
11 201934
12 201947
13 201754
14 201765
15 201711
16 20166
17 20151

About Vivian Chua

Vivian Chua is a scholar working on Ophthalmology, Cell Biology and Oncology, having authored 17 papers that have together received 326 indexed citations. Recurring topics across this work include Ocular Oncology and Treatments (13 papers), Ubiquitin and proteasome pathways (6 papers), Cancer-related Molecular Pathways (5 papers), Hippo pathway signaling and YAP/TAZ (4 papers), Microtubule and mitosis dynamics (3 papers), Retinal Development and Disorders (2 papers), Drug Transport and Resistance Mechanisms (2 papers) and Immunotherapy and Immune Responses (2 papers). The work is most often cited by research in Ophthalmology (180 citations), Immunology (82 citations) and Oncology (99 citations). Vivian Chua has collaborated with scholars based in United States, Australia and South Korea. Frequent co-authors include Andrew E. Aplin, Timothy J. Purwin, Takami Sato, Philip Wedegaertner, Jeffrey Benovic, Mizue Terai, Anna Han, Richard D. Carvajal, Michael A. Davies and Gary K. Schwartz.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026